Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Amdizalisib · HMPL-689

Small molecule · Inhibitor of phosphatidylinositol 3-kinase delta (PI3Kd) (PIK3CD) · developed by Hutchmed

Phase 2 Most advanced trial (none active)
HCM Developer
1 Registered trials

What is Amdizalisib?

Amdizalisib (HMPL-689) is an orally bioavailable, selective inhibitor of the delta isoform of phosphatidylinositide 3-kinase (PI3Kd). It binds PI3Kd and blocks PI3Kd/AKT signaling and B-cell activation, reducing proliferation and inducing cell death in PI3Kd-overexpressing tumor cells. It is studied in relapsed or refractory lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
HMPL-689
Drug type
Small molecule
Targets
phosphatidylinositol 3-kinase delta (PI3Kd) (PIK3CD)
Mechanism
Inhibitor of phosphatidylinositol 3-kinase delta (PI3Kd) (PIK3CD)
Pathways
PI3K/AKT signaling, B-cell receptor signaling
Therapy area
Oncology
Developer
Hutchmed (HCM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
F3YMY7783P

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05713110 Phase 2 Relapsed/Refractory Lymphoma Completed HCM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsed/Refractory Lymphoma

Other drugs acting on PIK3CD

More from Hutchmed

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.

Follow HCM, the company behind Amdizalisib

See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HCM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.